Baidu
map

Nat Med:曹雪涛团队发现乳腺癌患者易发淋巴结转移新机制

2019-01-16 佚名 科学网

肿瘤原发灶能够诱导远端转移器官中基质和相关免疫细胞成分与功能变化,形成一个利于肿瘤细胞定居生长“土壤”的 “肿瘤转移前微环境”。

肿瘤原发灶能够诱导远端转移器官中基质和相关免疫细胞成分与功能变化,形成一个利于肿瘤细胞定居生长“土壤”的 “肿瘤转移前微环境”。

淋巴结是重要的免疫器官,也是肿瘤最常见的转移部位,肿瘤淋巴结转移是临床判断患者预后的重要指标。因此,探索肿瘤淋巴结微环境变化机制、寻找预测和干预肿瘤转移的靶标和策略具有非常重要的临床意义。

中国工程院院士、南开大学校长曹雪涛与第二军医大学医学免疫学国家重点实验室副教授顾炎、天津医科大学附属肿瘤医院教授付丽等合作,揭示了B细胞能够通过分泌靶向肿瘤抗原HSPA4的病理性抗体,促进乳腺癌淋巴结转移。相关研究结果在线发表于1月15日《自然·医学》。

曹雪涛在接受记者采访时表示:“抗体靶向治疗是目前肿瘤治疗的重要方式之一,2018年的诺奖就是颁发给两位应用免疫抑制性抗体开展肿瘤免疫治疗的免疫学家。”

众所周知,B淋巴细胞可以分泌抗体,执行体液免疫功能。“然而,临床报道显示,某些类型的肿瘤(如乳腺癌、头颈部肿瘤、妇科肿瘤等)患者体内若有较高水平的抗体,则患者预后较差。”曹雪涛说,“而其中具体的机制及肿瘤患者体内存在的抗体的促瘤效应并未明了,尤其是对于B淋巴细胞及其分泌的抗体在肿瘤淋巴结转移中的功能知之甚少。”

研究团队利用小鼠乳腺癌原位模型,发现在肿瘤转移前,引流淋巴结中B细胞的比例与数量显著增加。并发现此类肿瘤驯化的B细胞可分泌大量抗体入血而促进乳腺癌淋巴结转移,实验性清除B细胞及其分泌的抗体,可以阻止乳腺癌淋巴结转移。

随后,研究人员利用蛋白质谱技术筛选到此类病理性抗体靶向的肿瘤膜抗原HSPA。进一步通过临床乳腺癌样本研究发现,乳腺癌患者血清存在高浓度抗HSPA4抗体水平,预示其易发淋巴结转移、患者生存期短、预后差。“这提示HSPA4抗体水平有望成为乳腺癌淋巴结转移预测、患者预后判断的指标,也为乳腺癌的治疗提供了新的潜在靶标。”曹雪涛说。

研究人员表示,本研究阐明了B细胞及抗体介导的体液免疫在淋巴结转移前微环境形成及肿瘤淋巴结转移中的重要功能。

此外,本研究首次发现除调节性B细胞介导的负向免疫调控功能外,B细胞能够通过分泌靶向肿瘤抗原的病理性抗体直接促进肿瘤转移,同时寻找到糖基化的肿瘤膜抗原在病理性抗体的产生及促转移中的重要功能,为深入认识体B细胞介导的体液免疫功能及肿瘤转移前微环境的形成提供了新的视角。

原始出处:



版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1883540, encodeId=e79d18835405d, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 05 22:31:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358593, encodeId=a14b358593c2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Sat Jan 19 08:26:33 CST 2019, time=2019-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358525, encodeId=046835852526, content=牛逼, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/RcTnA7USB0BHYVDd4N5jXBwvfhPMQt8C9XM1nhvxDG7YL5Afnib1CEaGZAnNDaicQtDFpwO8DKLuicLsFXDrAzYow/132, createdBy=27ea2111787, createdName=佳虎, createdTime=Fri Jan 18 13:50:13 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293059, encodeId=84d2129305964, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302517, encodeId=e2ba130251e97, content=<a href='/topic/show?id=7be06602886' target=_blank style='color:#2F92EE;'>#淋巴结转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66028, encryptionId=7be06602886, topicName=淋巴结转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351475, encodeId=aa3013514e5ee, content=<a href='/topic/show?id=c6e06030207' target=_blank style='color:#2F92EE;'>#曹雪涛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60302, encryptionId=c6e06030207, topicName=曹雪涛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571150, encodeId=3aad15e115044, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609491, encodeId=1f7e160949125, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358374, encodeId=e3da3583e4c4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Jan 16 22:35:43 CST 2019, time=2019-01-16, status=1, ipAttribution=)]
    2019-11-05 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1883540, encodeId=e79d18835405d, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 05 22:31:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358593, encodeId=a14b358593c2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Sat Jan 19 08:26:33 CST 2019, time=2019-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358525, encodeId=046835852526, content=牛逼, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/RcTnA7USB0BHYVDd4N5jXBwvfhPMQt8C9XM1nhvxDG7YL5Afnib1CEaGZAnNDaicQtDFpwO8DKLuicLsFXDrAzYow/132, createdBy=27ea2111787, createdName=佳虎, createdTime=Fri Jan 18 13:50:13 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293059, encodeId=84d2129305964, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302517, encodeId=e2ba130251e97, content=<a href='/topic/show?id=7be06602886' target=_blank style='color:#2F92EE;'>#淋巴结转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66028, encryptionId=7be06602886, topicName=淋巴结转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351475, encodeId=aa3013514e5ee, content=<a href='/topic/show?id=c6e06030207' target=_blank style='color:#2F92EE;'>#曹雪涛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60302, encryptionId=c6e06030207, topicName=曹雪涛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571150, encodeId=3aad15e115044, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609491, encodeId=1f7e160949125, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358374, encodeId=e3da3583e4c4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Jan 16 22:35:43 CST 2019, time=2019-01-16, status=1, ipAttribution=)]
    2019-01-19 phoebeyan520

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1883540, encodeId=e79d18835405d, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 05 22:31:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358593, encodeId=a14b358593c2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Sat Jan 19 08:26:33 CST 2019, time=2019-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358525, encodeId=046835852526, content=牛逼, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/RcTnA7USB0BHYVDd4N5jXBwvfhPMQt8C9XM1nhvxDG7YL5Afnib1CEaGZAnNDaicQtDFpwO8DKLuicLsFXDrAzYow/132, createdBy=27ea2111787, createdName=佳虎, createdTime=Fri Jan 18 13:50:13 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293059, encodeId=84d2129305964, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302517, encodeId=e2ba130251e97, content=<a href='/topic/show?id=7be06602886' target=_blank style='color:#2F92EE;'>#淋巴结转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66028, encryptionId=7be06602886, topicName=淋巴结转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351475, encodeId=aa3013514e5ee, content=<a href='/topic/show?id=c6e06030207' target=_blank style='color:#2F92EE;'>#曹雪涛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60302, encryptionId=c6e06030207, topicName=曹雪涛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571150, encodeId=3aad15e115044, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609491, encodeId=1f7e160949125, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358374, encodeId=e3da3583e4c4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Jan 16 22:35:43 CST 2019, time=2019-01-16, status=1, ipAttribution=)]
    2019-01-18 佳虎

    牛逼

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1883540, encodeId=e79d18835405d, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 05 22:31:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358593, encodeId=a14b358593c2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Sat Jan 19 08:26:33 CST 2019, time=2019-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358525, encodeId=046835852526, content=牛逼, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/RcTnA7USB0BHYVDd4N5jXBwvfhPMQt8C9XM1nhvxDG7YL5Afnib1CEaGZAnNDaicQtDFpwO8DKLuicLsFXDrAzYow/132, createdBy=27ea2111787, createdName=佳虎, createdTime=Fri Jan 18 13:50:13 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293059, encodeId=84d2129305964, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302517, encodeId=e2ba130251e97, content=<a href='/topic/show?id=7be06602886' target=_blank style='color:#2F92EE;'>#淋巴结转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66028, encryptionId=7be06602886, topicName=淋巴结转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351475, encodeId=aa3013514e5ee, content=<a href='/topic/show?id=c6e06030207' target=_blank style='color:#2F92EE;'>#曹雪涛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60302, encryptionId=c6e06030207, topicName=曹雪涛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571150, encodeId=3aad15e115044, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609491, encodeId=1f7e160949125, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358374, encodeId=e3da3583e4c4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Jan 16 22:35:43 CST 2019, time=2019-01-16, status=1, ipAttribution=)]
    2019-01-18 sodoo
  5. [GetPortalCommentsPageByObjectIdResponse(id=1883540, encodeId=e79d18835405d, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 05 22:31:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358593, encodeId=a14b358593c2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Sat Jan 19 08:26:33 CST 2019, time=2019-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358525, encodeId=046835852526, content=牛逼, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/RcTnA7USB0BHYVDd4N5jXBwvfhPMQt8C9XM1nhvxDG7YL5Afnib1CEaGZAnNDaicQtDFpwO8DKLuicLsFXDrAzYow/132, createdBy=27ea2111787, createdName=佳虎, createdTime=Fri Jan 18 13:50:13 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293059, encodeId=84d2129305964, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302517, encodeId=e2ba130251e97, content=<a href='/topic/show?id=7be06602886' target=_blank style='color:#2F92EE;'>#淋巴结转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66028, encryptionId=7be06602886, topicName=淋巴结转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351475, encodeId=aa3013514e5ee, content=<a href='/topic/show?id=c6e06030207' target=_blank style='color:#2F92EE;'>#曹雪涛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60302, encryptionId=c6e06030207, topicName=曹雪涛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571150, encodeId=3aad15e115044, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609491, encodeId=1f7e160949125, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358374, encodeId=e3da3583e4c4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Jan 16 22:35:43 CST 2019, time=2019-01-16, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1883540, encodeId=e79d18835405d, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 05 22:31:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358593, encodeId=a14b358593c2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Sat Jan 19 08:26:33 CST 2019, time=2019-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358525, encodeId=046835852526, content=牛逼, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/RcTnA7USB0BHYVDd4N5jXBwvfhPMQt8C9XM1nhvxDG7YL5Afnib1CEaGZAnNDaicQtDFpwO8DKLuicLsFXDrAzYow/132, createdBy=27ea2111787, createdName=佳虎, createdTime=Fri Jan 18 13:50:13 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293059, encodeId=84d2129305964, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302517, encodeId=e2ba130251e97, content=<a href='/topic/show?id=7be06602886' target=_blank style='color:#2F92EE;'>#淋巴结转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66028, encryptionId=7be06602886, topicName=淋巴结转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351475, encodeId=aa3013514e5ee, content=<a href='/topic/show?id=c6e06030207' target=_blank style='color:#2F92EE;'>#曹雪涛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60302, encryptionId=c6e06030207, topicName=曹雪涛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571150, encodeId=3aad15e115044, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609491, encodeId=1f7e160949125, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358374, encodeId=e3da3583e4c4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Jan 16 22:35:43 CST 2019, time=2019-01-16, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1883540, encodeId=e79d18835405d, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 05 22:31:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358593, encodeId=a14b358593c2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Sat Jan 19 08:26:33 CST 2019, time=2019-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358525, encodeId=046835852526, content=牛逼, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/RcTnA7USB0BHYVDd4N5jXBwvfhPMQt8C9XM1nhvxDG7YL5Afnib1CEaGZAnNDaicQtDFpwO8DKLuicLsFXDrAzYow/132, createdBy=27ea2111787, createdName=佳虎, createdTime=Fri Jan 18 13:50:13 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293059, encodeId=84d2129305964, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302517, encodeId=e2ba130251e97, content=<a href='/topic/show?id=7be06602886' target=_blank style='color:#2F92EE;'>#淋巴结转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66028, encryptionId=7be06602886, topicName=淋巴结转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351475, encodeId=aa3013514e5ee, content=<a href='/topic/show?id=c6e06030207' target=_blank style='color:#2F92EE;'>#曹雪涛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60302, encryptionId=c6e06030207, topicName=曹雪涛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571150, encodeId=3aad15e115044, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609491, encodeId=1f7e160949125, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358374, encodeId=e3da3583e4c4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Jan 16 22:35:43 CST 2019, time=2019-01-16, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1883540, encodeId=e79d18835405d, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 05 22:31:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358593, encodeId=a14b358593c2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Sat Jan 19 08:26:33 CST 2019, time=2019-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358525, encodeId=046835852526, content=牛逼, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/RcTnA7USB0BHYVDd4N5jXBwvfhPMQt8C9XM1nhvxDG7YL5Afnib1CEaGZAnNDaicQtDFpwO8DKLuicLsFXDrAzYow/132, createdBy=27ea2111787, createdName=佳虎, createdTime=Fri Jan 18 13:50:13 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293059, encodeId=84d2129305964, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302517, encodeId=e2ba130251e97, content=<a href='/topic/show?id=7be06602886' target=_blank style='color:#2F92EE;'>#淋巴结转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66028, encryptionId=7be06602886, topicName=淋巴结转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351475, encodeId=aa3013514e5ee, content=<a href='/topic/show?id=c6e06030207' target=_blank style='color:#2F92EE;'>#曹雪涛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60302, encryptionId=c6e06030207, topicName=曹雪涛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571150, encodeId=3aad15e115044, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609491, encodeId=1f7e160949125, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358374, encodeId=e3da3583e4c4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Jan 16 22:35:43 CST 2019, time=2019-01-16, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1883540, encodeId=e79d18835405d, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Nov 05 22:31:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358593, encodeId=a14b358593c2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Sat Jan 19 08:26:33 CST 2019, time=2019-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358525, encodeId=046835852526, content=牛逼, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/RcTnA7USB0BHYVDd4N5jXBwvfhPMQt8C9XM1nhvxDG7YL5Afnib1CEaGZAnNDaicQtDFpwO8DKLuicLsFXDrAzYow/132, createdBy=27ea2111787, createdName=佳虎, createdTime=Fri Jan 18 13:50:13 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293059, encodeId=84d2129305964, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302517, encodeId=e2ba130251e97, content=<a href='/topic/show?id=7be06602886' target=_blank style='color:#2F92EE;'>#淋巴结转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66028, encryptionId=7be06602886, topicName=淋巴结转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351475, encodeId=aa3013514e5ee, content=<a href='/topic/show?id=c6e06030207' target=_blank style='color:#2F92EE;'>#曹雪涛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60302, encryptionId=c6e06030207, topicName=曹雪涛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571150, encodeId=3aad15e115044, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609491, encodeId=1f7e160949125, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jan 18 13:31:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358374, encodeId=e3da3583e4c4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Jan 16 22:35:43 CST 2019, time=2019-01-16, status=1, ipAttribution=)]
    2019-01-16 医者仁心5538

    学习了

    0

相关资讯

Cell Rep:一箭双雕!乳腺癌药物将肺癌组织缩小66.7%!

乳腺癌和肺癌这两种看似八杆子打不着的两种肿瘤或许在发病机制上有着不为人知的相似性。我们在很久以前就知道乳腺癌中有一种类型是由于EGFR基因突变导致,但其实肺癌类型中也有一种具有相似的EGFR基因突变。

百例挑一:三阴性局部进展期乳腺癌新辅助化疗1例

36岁,已婚。主诉:2018年3月28日因“发现右乳肿块半个月”入院。

Blood:SNPs对胸部放疗的HL患者患乳腺癌风险的影响

中心点:霍奇金淋巴瘤患者发生放疗诱导型乳腺癌的风险与一般人群中乳腺癌的PRS密切相关。基于9个在HL后乳腺癌的发生中与RT相互作用的SNPs的PRS,也可增加RT诱导型乳腺癌的风险。摘要:采用胸部放疗(RT)的霍奇金淋巴瘤(HL)女性患者患乳腺癌的风险高。遗传因素对该风险的贡献度尚不明确。Annemieke W.J. Opstal-van Winden等研究人员对327位采用胸部RT治疗HL的随后

Nat Cell Biol:科学家有望开发出抑制癌症转移的新型疗法

某些乳腺癌患者在接受外科手术之前会进行化疗进行治疗,这种肿瘤辅助疗法能帮助减少肿瘤的尺寸从而促进乳腺保留手术的进行,甚至能够完全清除肿瘤;在这种情况下,很多乳腺癌患者在术后生活中很有可能并不会出现癌症复发的状况。但在化疗治疗中并不是所有的肿瘤都会发生萎缩,如果肿瘤对辅助疗法产生耐受的话,其就会引发高风险的转移性疾病,也就是说,肿瘤细胞会转移到机体的多个其它器官中,比如骨骼和肺部等,这是因为当原发性

JAMA Oncol:女性乳腺癌发病风险与体重、体脂相关吗?

世界卫生组织将体重指数(BMI)≥25kg/m2定义为超重、≥30 kg/m2定义为肥胖。既往研究证实,超重和肥胖均与乳腺癌发生风险增加相关。然而BMI只是一个初略衡量指标,不能区分脂肪和肌肉。近期发布在JAMA Oncology杂志的一项研究,评估了BMI正常的绝经后女性,体脂质量与乳腺癌发生风险的关系。

JAMA Oncol:激素受体阳性男性乳腺癌的辅助内分泌治疗应用现状及疗效观察

男性乳腺癌非常少见,因此缺少大宗临床研究数据,治疗推荐多由女性乳腺癌外推而来。多数男性乳腺癌为激素受体阳性,内分泌治疗是很重要的治疗组成。内分泌治疗在女性乳腺癌辅助治疗时有生存获益,那么对于激素受体阳性的男性乳腺癌患者而言也是一样的结果吗?近期《JAMA Oncology》刊登了一篇来源于宾夕法尼亚大学佩雷尔曼医学院放射肿瘤学系专家的文章。对激素受体阳性的男性乳腺癌患者使用辅助内分泌治疗的应用现状

Baidu
map
Baidu
map
Baidu
map